Carregant...
Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
Background: Reduced glutathione (GSH) is an endogenously synthesized tripeptide depleted early in the course of Parkinson’s disease (PD) and GSH augmentation has been proposed as a therapeutic strategy in PD. Objective: This Phase IIb study was designed to evaluate whether a Phase III study of intra...
Guardat en:
| Publicat a: | J Parkinsons Dis |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
IOS Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5438472/ https://ncbi.nlm.nih.gov/pubmed/28436395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-161040 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|